Search

Displaying results 5511 - 5520 of 7897 in total
  1. Drug

    HRS-1167

    go.drugbank.com/drugs/DB18703
    Investigational

    HRS-1167 is under investigation in clinical trial NCT05473624 (Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors).

  2. Drug

    RCT1100

    go.drugbank.com/drugs/DB18830
    Investigational

    RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]

  3. Drug

    Yeast beta-D-glucan

    go.drugbank.com/drugs/DB19271
    Investigational

    Yeast beta-D-glucan is under investigation in clinical trial NCT00632008 (Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers).

  4. Drug

    GSK-239512

    go.drugbank.com/drugs/DB15120
    Investigational

    GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).

  5. Drug

    Fosmanogepix

    go.drugbank.com/drugs/DB15183
    Investigational

    Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).

  6. Drug

    Tiazofurine

    go.drugbank.com/drugs/DB13243
    Experimental

    Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].

  7. Drug

    1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

    go.drugbank.com/drugs/DB01562
    ExperimentalIllicit

    1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP) is a synthetic analogue of meperidine. It is sold as a "synthetic heroin."

  8. Drug

    HCV-086

    go.drugbank.com/drugs/DB05884
    Experimental

    HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

  9. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  10. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.